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Abstract In Japan, the annual number of deaths from
gastric cancer is approximately 50,000 and there has been
no change over the last 50 years. So far, all efforts have
been directed toward improving the detection of early
gastric cancer by barium X-ray and endoscopy, since early
cancer has a good prognosis, resulting in Japan having the
best diagnostic capability for early gastric cancer world-
wide. The 5-year survival rate of gastric cancer patients
exceeds 60 % in Japan and is much higher than that in
Europe and the US (20 %) because of this superior diag-
nosis of early gastric cancer. In February 2013, national
health insurance coverage for Helicobacter pylori eradi-
cation therapy to treat H. pylori-associated chronic gastritis
became available in Japan. H. pylori-associated gastritis
leads to development of gastric and duodenal ulcers and
gastric polyps. Therefore, providing treatment for gastritis
is likely to substantially decrease the prevalence of both
gastric and duodenal ulcers and polyps. Because treatment
for H. pylori-associated gastritis, which leads to atrophic
gastritis and gastric cancer, is now covered by health
insurance in Japan, a strategy to eliminate gastric cancer-
related deaths by taking advantage of this innovation was
planned. According to this strategy, patients with gastritis
will be investigated for H. pylori infection and those who
are positive will receive eradication therapy followed by
periodic surveillance. If this strategy is implemented,
deaths from gastric cancer in Japan will decrease dramat-
ically after 10–20 years.
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Introduction
After the discovery of Helicobacter pylori (H. pylori) in
1983 [1], the causal relationship between this bacterium
and gastritis and/or gastric cancer has been steadily eluci-
dated. In 1994, H. pylori was classified as a definite car-
cinogen by the International Agency for Research on
Cancer (IARC) of the World Health Organization (WHO)
[2]. Subsequently, many clinical studies were conducted in
various countries to determine whether eradication of
H. pylori could contribute to the prevention of gastric cancer.
However, the very low incidence of gastric cancer among
the subjects meant that sufficient data for statistical ana-
lysis were not obtained. In 2008, randomized multicenter
clinical study conducted in Japan revealed that eradication
of H. pylori reduced the incidence of secondary gastric
cancer by about two-thirds after endoscopic mucosal
resection (EMR) of early gastric cancer [3], suggesting the
usefulness of H. pylori eradication for prevention of gastric
cancer. However, this study also showed that H. pylori
eradication did not completely eliminate gastric cancer.
Therefore, to eliminate gastric cancer, periodical surveil-
lance would be required after H. pylori eradication. Thus,
to achieve the elimination of gastric cancer in Japan, the
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important issue is how to combine primary prevention
through H. pylori eradication with secondary prevention
through surveillance. Fortunately, the Ministry of Health,
Labour and Welfare of Japan (MHLW) approved national
health insurance coverage for eradication therapy in
patients with gastritis caused by H. pylori infection
(chronic active gastritis) on February 21 in 2013 for the
first time in the world. Here, we present a roadmap for the
elimination of gastric cancer in Japan, focusing on eradi-
cation of H. pylori.
Current status and characteristics of screening
for gastric cancer in Japan
Approximately 60 % of gastric cancer patients worldwide
are found in only three East Asian countries (Japan, China,
and Korea), and the disease seems to be endemic to this
area [4]. Gastric cancer was the most common cause of
cancer death in Japan until it was replaced by lung cancer
in 1995 [5]. Thanks to concerted efforts by clinical and
fundamental researchers, the concept of early gastric can-
cer was proposed in Japan in 1963. At that time, early
gastric cancer was defined as a lesion with infiltration of
tumor cells limited to the mucosa or submucosa, irre-
spective of lymph node metastasis [6, 7].
The prognosis of early gastric cancer is far better than
that of advanced cancer, with a 5-year survival rate
exceeding 90 % [8]. Therefore, many studies in Japan have
focused on how to diagnose effectively early gastric can-
cer. As a result, early cancer now accounts for nearly 60 %
of all gastric cancers detected in Japan. This has not been
reported in any other country and suggests high diagnostic
capability for early cancer in the country. The survival rate
of gastric cancer patients depends on the stage of their
tumor. It exceeds 90 % for stage I (including early gastric
cancer), while it is under 20 % for stage IV. Thus, a higher
stage means a worse prognosis [9], hence it is important to
detect as many early cancers as possible for improvement
of gastric cancer mortality. The efforts made so far have
led to an overall 5-year survival rate of better than 65 % for
gastric cancer patients in Japan [9]. In other countries,
including the US and Europe, the 5-year survival rate of
gastric cancer patients is reported to be only 10–25 %
(Fig. 1) [10–12]. This is not because treatment of gastric
cancer is superior in Japan to that in other countries, but
because the detection rate of early cancer is much lower
outside Japan. In other words, the stage distribution of
gastric cancer patients receiving treatment in Japan is likely
to be different from that in other countries where there is
little emphasis on detecting early gastric cancer. In the US
and Europe, intramucosal carcinoma is not even considered
to be cancer and is classified as dysplasia [13]. Thus,
researchers in the US and Europe have speculated that the
diagnosis and treatment of precancerous lesions as early
gastric cancer improves the prognosis in Japan compared
with other countries. There is undoubtedly a difference of
diagnostic criteria between Japan and the US/Europe.
While Japanese pathologists make a diagnosis of gastric
cancer based on the presence of atypical nuclei in gastric
mucosal cells and atypical glandular or ductal structures,
pathologists in the US and Europe will diagnose gastric
dysplasia instead of gastric cancer when atypical glandular
and ductal structures do not extend beyond the muscularis
mucosa [13]. This difference in the diagnostic criteria for
gastric cancer between Japan and the US/Europe is an issue
that seems to be difficult to resolve [14]. However, based
on the findings that 30–60 % of lesions diagnosed as dys-
plasia show progression to gastric cancer within a few
years [15–17] and that examination of larger biopsy spec-
imens leads to diagnosis of more lesions as cancer [18],
high-grade dysplasia should be classified as intramucosal
gastric cancer and be treated aggressively in order to
improve the prognosis of gastric cancer.
In Japan, endoscopic surgery is commonly performed
for intramucosal gastric cancer, a form of early gastric
cancer, while such treatment is uncommon in Europe and
the US where intramucosal lesions are not regarded as
cancerous. Even if physicians in Europe and the US accept
the concept of early gastric cancer, they need to develop
techniques for diagnosis and endoscopic surgery [17].
Possibly because of inadequate diagnostic techniques for
early gastric cancer, the prognosis of gastric cancer is poor
in other countries. The skill of Japanese physicians with
regard to early diagnosis and endoscopic treatment of
gastric cancer is unsurpassed and contributes greatly to the
management of patients with this cancer in Japan. To
achieve improvement of the prognosis of gastric cancer in
other countries, it would be necessary for the concept of
early gastric cancer to be accepted and the same level of
technical skill in the management of early gastric cancer as
in Japan to be established, which could lead to the pro-
motion of gastric cancer elimination by combining
H. pylori eradication therapy with surveillance.
Fig. 1 Five-year survival rate in Japan, US and Europe (%)
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Prevention of gastric cancer by eradication of H. pylori
As it has become clear that H. pylori infection is an
important risk factor for gastric cancer, the issue of whe-
ther H. pylori eradication therapy can decrease the inci-
dence of gastric cancer has attracted increasing attention.
Intervention studies to assess the preventative effect of
H. pylori eradication on gastric cancer have been con-
ducted in healthy individuals worldwide. However, the
incidence of gastric cancer is very low in the US and
Europe, and the study populations were not large enough to
detect a significant effect of eradication therapy, resulting
in the discontinuation of most studies [19].
In 2004, a report on a large intervention study performed
in China was published [20]. This study involved 1,630
H. pylori-infected residents of Fujian province in China
where the mortality rate due to gastric cancer is high.
During the follow-up period, gastric cancer developed in 7
and 11 subjects from the eradication and placebo groups,
respectively, and there was no significant difference
between the two groups (p = 0.33). However, among
patients without precancerous lesions (atrophy, intestinal
metaplasia, or dysplasia), there were no cases of gastric
cancer in the H. pylori eradication group and there was a
significantly lower incidence of gastric cancer compared
with the placebo group (n = 6) (p = 0.02). Interestingly,
all of the cancers diagnosed after H. pylori eradication
were advanced and there were no cases of early gastric
cancer, which was a surprising result in view of the situ-
ation in Japan where at least 60 % of gastric cancers are
diagnosed at an early stage. Such an outcome suggests that
the endoscopists involved in this study might not be skilled
in the diagnosis of early gastric cancer. Accordingly, the
patients who were classified as having atrophic gastritis or
intestinal metaplasia may well have included many patients
with early gastric cancer. H. pylori infection is strongly
associated with early gastric cancer rather than advanced
cancer [21], suggesting that investigation of the prevention
of gastric cancer by H. pylori eradication therapy is prob-
lematic outside Japan because early gastric cancer is
unlikely to be diagnosed.
Assessment of the design of a new prospective study on
the basis of previous studies indicated that a clinical trial
with a small sample size and short follow-up period should
enroll patients with early gastric cancer who have under-
gone EMR, since they represent the population most likely
to develop advanced gastric cancer. The annual incidence of
gastric cancer has been reported to be only 0.1–0.4 % in
H. pylori-positive patients with atrophic gastritis [22, 23],
while the annual incidence of metachronous recurrence is
far higher (3–5 %) in patients who have undergone endo-
scopic surgery for early gastric cancer [24, 25]. We inves-
tigated the metachronous recurrence of gastric cancer in 544
patients who had undergone endoscopic treatment for early
gastric cancer. They were randomly allocated to H. pylori
eradication or non-eradication groups and were followed up
by annual endoscopic examination for 3 years. As a result,
metachronous recurrence was detected in 9 and 24 subjects
from the eradication group and the non-eradication group,
respectively, and the former had a significantly lower
relapse rate (p \ 0.01 according to intention-to-treat ana-
lysis) [3]. This prospective study had an adequate sample
size to provide a definitive answer to the long controversial
issue of whether gastric cancer could be prevented through
H. pylori eradication. It demonstrated that H. pylori eradi-
cation therapy reduced the incidence of intestinal type
gastric cancer by at least two-thirds and this effect was
noted irrespective of whether patients had atrophic gastritis,
intestinal metaplasia, or early gastric cancer. Thus, it was
confirmed that most gastric cancer is associated with
H. pylori infection and that the disease can be effectively
prevented by eradication of this microorganism.
In 2009, a large-scale cohort study was reported, in
which about 80,000 patients in Taiwan were followed up
for 10 years after H. pylori eradication therapy [26]. The
patients were assigned to an early eradication group
(H. pylori eradication therapy was provided at the time of
diagnosis) or a late eradication group (eradication therapy
was performed at 1 year or more after diagnosis). It was
found that the incidence of gastric cancer was markedly
lower in the early eradication group than in the late erad-
ication group. This study is important because it demon-
strates that H. pylori eradication therapy inhibits the
development of gastric cancer and that earlier eradication is
more effective.
In 2006, You et al. [27] reported a study of 3,365
patients in China who were randomized to an H. pylori
eradication group, a garlic group, or a vitamin group and
were followed for 7.3 years, with the result being no
inhibition of gastric cancer in any of the groups. However,
longer follow-up for 15 years subsequently revealed sig-
nificant inhibition of gastric cancer in the H. pylori eradi-
cation group (odds ratio, 0.61; p = 0.032) [28]. Although
there was no significant preventive effect on gastric cancer
of eradication therapy in the original randomized study,
longer observation revealed a significant effect.
The above-mentioned three studies performed in East
Asia provide strong evidence that H. pylori eradication
therapy is effective for inhibiting gastric cancer. In Japan,
Maehata et al. investigated the long-term clinical outcome
following H. pylori eradication therapy and whether it
prevented metachronous gastric cancer. They reported that
eradication therapy inhibited the development of metach-
ronous gastric cancer for 5 years, but there was no signif-
icant difference after longer follow-up [29]. However, the
mean observation period of this study was only 3 years and
J Gastroenterol (2014) 49:1–8 3
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the 10-year prognosis was assessed in very few patients,
leading to lack of reliability. That is, the findings about the
short-term prognosis may well be accurate, but no con-
clusion can be drawn regarding the long-term outcome.
After the JGSG study was completed and data obtained
at 8–10 years were analyzed, it was found that there was
still a difference in the incidence of metachronous gastric
cancer between the H. pylori eradication and non-eradi-
cation groups [30]. This indicates that the preventive effect
of eradication therapy on gastric cancer persists for a long
time.
Health insurance coverage for H. pylori eradication
therapy in Japan
Cancers are classified into two broad categories, which are
lifestyle-related and infection-related cancers. In the US
and Europe, cancers related to infection account for a low
percentage (10 % or less) of all cancers [31, 32]. In Japan,
however, it has become clear that infection-related cancers
account for approximately 25 %, including liver cancer
caused by hepatitis viruses, cervical cancer due to papil-
lomavirus, and gastric cancer related to H. pylori. Although
cervical cancer is uncommon and accounts for a low per-
centage (1.3 %) of all cancers, gastric cancer and liver
cancer account for about 17 and 6.5 %, respectively, and
the total for these three cancers is nearly 25 % [33]. Since
it has become clear that most gastric cancer is due to
H. pylori infection rather than lifestyle factors, it is time for
major revision of the preventative strategies for gastric
cancer. When it is suspected that a cancer is caused by
infection, proactive preventative measures are likely to
lead to a dramatic decrease in the incidence of that cancer,
resulting in a significant decrease of cancer mortality. In
Japan, preventative measures for liver cancer have been
focused on hepatitis virus infection since 2002, leading to a
reduction of mortality [34, 35]. However, the annual
number of deaths from gastric cancer has remained at
around 50,000 for the last few decades [36], suggesting that
the current preventative measures are inadequate (Fig. 2).
Even though there is a difference in the causative agent
between liver cancer (viruses) and gastric cancer (a bac-
terium), preventive measures for gastric cancer should not
be completely different from those for liver cancer. Thus,
the fundamental measures for preventing gastric cancer
should be shifted from conventional secondary prevention
based on barium X-ray screening to primary prevention
focused on H. pylori eradication therapy.
In 2009, the Japanese Society for Helicobacter Research
published a guideline in which it is recommended that all
H. pylori-infected people receive bacterial eradication
therapy [37]. In response to this, the MHLW approved the
extension of national health insurance coverage to H. pylori
eradication therapy for three indications [i.e., patients with
gastric mucosa-associated lymphoid tissue (MALT) lym-
phoma, patients who have undergone endoscopic surgery
for early gastric cancer, and patients with idiopathic
thrombocytopenic purpura (ITP)], in addition to patients
with gastric and duodenal ulcer. This was the first time in
the world that insurance coverage has been provided for
H. pylori eradication therapy for indications other than
gastric and duodenal ulcer and represents an innovative
approach. Regarding the potential expansion of health
insurance coverage for eradication therapy to include
patients with chronic gastritis, the Japanese Society of
Gastroenterology, the Japan Gastroenterological Endos-
copy Society, and the Japanese Society for Helicobacter
Research submitted a joint petition to the Minister of the
MHLW. This public knowledge-based application led to the
inclusion of H. pylori eradication therapy for patients with
chronic gastritis on February 21, 2013. The MHLW notifi-
cation states that eradication therapy is covered by the national
health insurance scheme when a patient with endoscopically
diagnosed chronic gastritis is positive for H. pylori.
Within a few months of being infected, gastritis with
neutrophil and lymphocyte infiltration develops in almost
100 % of patients who have H. pylori infection. Such
gastritis is called chronic active gastritis and is said to be
specific to H. pylori infection [38]. Gastritis caused by
H. pylori develops as a biological defense to the infection,
resulting in the production of inflammatory cytokines such
as IL-1 and IL-8 and the expansion of gastric mucosal
inflammation [39]. Persistent inflammation gradually
increases the fragility of the gastric mucosa and H. pylori-
associated gastritis progresses to atrophic gastritis over
time. It has been demonstrated that progression takes
Fig. 2 Changes of deaths of gastric cancer and liver cancer in Japan
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10–20 years in about 80 % of Japanese patients [40], and
some cases of atrophic gastritis then progress to intestinal
type gastric cancer. Correa’s hypothesis has been widely
accepted, which states that gastritis progresses to intestinal
metaplasia, dysplasia, and then gastric cancer [41], and it
has been virtually proved by the discovery of H. pylori.
The effects of gastric acid and stress on a background of
H. pylori-associated gastritis can lead to the development
of peptic ulcer. In contrast, gastritis that is not associated
with H. pylori usually does not progress to ulceration even when
stress occurs. It has become obvious that H. pylori-associated
gastritis is also closely associated with gastric MALT lym-
phoma, functional dyspepsia (FD), hyperplastic gastric pol-
yps, idiopathic thrombocytopenic purpura (ITP) and diffuse
type gastric cancer (Fig. 3) [42, 43] Thus, H. pylori-associated
gastritis is the underlying cause of almost all gastric diseases,
hence treatment of this gastritis through bacterial eradication
therapy is likely to prevent most gastric conditions, including
gastric cancer.
Kodama et al. observed the 10-year course by obtaining
biopsy specimens from 5 different sites of the gastric
mucosa, and found that the activity score and inflammation
improved immediately after H. pylori eradication therapy
and then remained stable for the next 10 years. They
reported that atrophic change took longer to improve leu-
kocytic infiltration, but nearly 80 % of the changes had
resolved after 10 years [44]. Their findings revealed
that eradication therapy improved atrophic changes of
H. pylori-associated gastritis, as well as leukocytic infiltra-
tion, indicating that this therapy is useful for the prevention of
gastric cancer.
Strategy and roadmap for the elimination of gastric
cancer in Japan
In order to eliminate gastric cancer in Japan, the strategy
for adolescents should be different from that for elderly
persons. This is because bacterial eradication in adoles-
cents achieves nearly 100 % prevention of gastric cancer,
but the incidence of this cancer increases with advancing
age [43, 45]. We recommend a test-and-treat approach as
the strategy for adolescents, which includes H. pylori
testing of junior high school and high school students,
followed by immediate H. pylori eradication therapy for
those with a positive result. Eradication in adolescents
should be able to prevent H. pylori-related diseases such as
gastric ulcer and gastric polyps, as well as preventing the
development of nearly 100 % of gastric cancers. It is
estimated that approximately 5 % of all teenagers in Japan
are positive for H. pylori [46], suggesting that the cost of
this approach would not be so high. Some local govern-
ments have already scheduled free H. pylori testing for
junior high school students.
The recent expansion of health insurance coverage
allows individuals with symptoms such as gastric heaviness
to present to hospital for the diagnosis and treatment of
H. pylori-associated gastritis. To obtain health insurance
coverage, endoscopy must be performed first for the
diagnosis of gastritis, and most patients seem to have
chronic gastritis by the time they undergo endoscopy. We
expect that many patients with gastric cancer will be dis-
covered during this endoscopic examination. This project
thus includes a form of endoscopic screening supported by
medical insurance. All patients in whom gastritis is diag-
nosed are supposed to receive H. pylori eradication ther-
apy. In patients with obvious atrophic gastritis, periodic
endoscopic follow-up is recommended every 1 or 2 years
even after eradication therapy, while patients with no or
mild atrophy and those who are negative for H. pylori
infection can be followed by optional screening (such as
personal medical check-up) instead of strategic screening
(Fig. 4).
In Japan, the success rate of H. pylori eradication ther-
apy is decreasing every year because of the increase in
bacteria resistant to clarithromycin, but secondary eradi-
cation therapy with metronidazole achieves a high success
rate ([95 %). That may be because resistance to metroni-
dazole is very low in Japan (about 5 %) where health
Fig. 3 Progress of H. pylori infection
Fig. 4 Strategy for elimination of gastric cancer deaths in Japan
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insurance coverage for administration of metronidazole is
limited and its use remains uncommon [36]. A recent
report indicated that third-line eradication therapy with
sitafloxacin was effective for 70 % of the patients in whom
secondary eradication therapy was ineffective [47].
Although it is not clear to what extent the use of erad-
ication therapy in patients with H. pylori-associated gas-
tritis will inhibit the development of gastric cancer, a good
model may be peptic ulcer for which H. pylori eradication
therapy was first covered by the Japanese national health
scheme in 2000. Since then, the incidence of peptic ulcer
has decreased dramatically by about 60 % over 10 years
(Fig. 5) [48]. In addition, the medical costs of treating
ulcers have decreased by no 47 % during that period.
Although it is unclear whether the results obtained with
gastric cancer will be comparable to those for peptic ulcer,
H. pylori eradication therapy (etiologic treatment) for
H. pylori-associated gastritis will lead to a long-term decrease
of gastric cancer. Such treatment will inhibit the development
of peptic ulcer and gastric polyps as well as gastric cancer,
suggesting a greater reduction of medical costs than that
achieved by providing insurance coverage for H. pylori
eradication therapy in patients with peptic ulcer.
There are two potential outcomes of the gastric cancer
elimination project suggested here with regard to gastric
cancer-related deaths in Japan. One is a definite decrease in
the incidence of gastric cancer resulting from the wide-
spread use of H. pylori eradication therapy (a direct effect
of this therapy). The other is a decrease in the number of
deaths resulting from an increase in the diagnosis of early
gastric cancer owing to mandatory endoscopy at the time of
presentation for chronic gastritis. The target would be to
eventually increase the proportion of early gastric cancer
from the current 60 % to around 90 %, which would make
it possible to increase the 5-year survival rate for gastric
cancer patients in Japan to approximately 90 %. Because
the baby boomer generation represents a huge population
turning 65 years old and entering the cancer-prone years,
the number of deaths from gastric cancer is likely to reach
60,000 in 2020 without any countermeasures. In contrast, if
the gastric cancer elimination project is successful and
about 50 % of persons with H. pylori infection receive
eradication therapy, the number of deaths from gastric
cancer will decrease to about 30,000 in 2020 (Fig. 6).
Conclusion
H. pylori eradication therapy for chronic gastritis achieved
the world’s first coverage by the Japanese national health
insurance scheme in 2013, making a dramatic decrease of
gastric cancer-related deaths more realistic. Combining
H. pylori eradication therapy with endoscopic surveillance
can prevent the development of gastric cancer. Even if
gastric cancer develops, most patients are likely to be
diagnosed while it is at an early stage, possibly resulting in
a large decrease of gastric cancer deaths.
Success with the elimination of gastric cancer in Japan
could lead other countries with a high incidence of gastric
cancer (China, Korea, and Latin American countries) to
consider a similar strategy, suggesting the potential for
elimination of gastric cancer around the world.
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